SZL P1-41 |
Catalog No.GC11869 |
SZL P1-41 est un inhibiteur spécifique de Skp2, se lie au domaine F-box de Skp2 pour empêcher l'association Skp1 et la formation du complexe Skp2 SCF. SZL P1-41, comme le déficit en Skp2, augmente l'apoptose/sénescence médiée par p27, alors qu'il altère la glycolyse induite par Akt. Activités anti-tumorales.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 222716-34-9
Sample solution is provided at 25 µL, 10mM.
SZL P1-41 is a specific Skp2 inhibitor, binds to the F-box domain of Skp2 to prevent Skp1 association and Skp2 SCF complex formation. SZL P1-41, like Skp2 deficiency, augments p27-mediated apoptosis/senescence, while it impairs Akt-driven glycolysis. Anti-tumor activities[1][2].
SZL P1-41 (5-20μM; 24 hours) induces endogenous p27 protein expression in PC3 cells and also induced expression of p21, another Skp2 substrate[1].
SZL P1-41 (40-80 mg/kg; i.p.) displays a potent effect on inhibiting prostate and lung tumor growth in Nude mice bearing A549 and PC3 tumor xenografts[1].
References:
[1]. Chan CH et al. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell. 2013 Aug 1;154(3):556-68.
[2]. Chan CH, et al. Skp2: a dream target in the coming age of cancer therapy. Cell Cycle. 2014;13(5):679-80.
Average Rating: 5
(Based on Reviews and 31 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *